What is HC Wainwright’s Estimate for TCRX FY2030 Earnings?

TScan Therapeutics, Inc. (NASDAQ:TCRX) – Equities researchers at HC Wainwright issued their FY2030 earnings estimates for shares of TScan Therapeutics in a research note issued on Wednesday, March 4th. HC Wainwright analyst A. Maldonado expects that the company will post earnings of ($0.09) per share for the year. HC Wainwright has a “Buy” rating and a $7.00 price objective on the stock. The consensus estimate for TScan Therapeutics’ current full-year earnings is ($1.12) per share.

TScan Therapeutics (NASDAQ:TCRX) last released its quarterly earnings data on Wednesday, March 4th. The company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($0.27) by $0.09. TScan Therapeutics had a negative return on equity of 73.33% and a negative net margin of 1,692.96%.The business had revenue of $2.57 million for the quarter.

TCRX has been the topic of several other reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of TScan Therapeutics in a report on Thursday, January 22nd. Morgan Stanley downgraded TScan Therapeutics from an “overweight” rating to an “equal weight” rating in a research note on Friday, November 14th. Finally, Wedbush boosted their price target on shares of TScan Therapeutics from $4.00 to $5.00 and gave the company an “outperform” rating in a research report on Thursday. Four equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, TScan Therapeutics has an average rating of “Hold” and a consensus price target of $6.20.

TScan Therapeutics Price Performance

NASDAQ TCRX traded up $0.07 on Thursday, hitting $1.15. The company had a trading volume of 381,579 shares, compared to its average volume of 489,636. The company’s fifty day moving average price is $1.06 and its 200-day moving average price is $1.40. TScan Therapeutics has a 12-month low of $0.88 and a 12-month high of $2.57. The company has a market capitalization of $64.98 million, a PE ratio of -1.02 and a beta of 1.03. The company has a debt-to-equity ratio of 0.23, a current ratio of 6.44 and a quick ratio of 6.44.

Insider Transactions at TScan Therapeutics

In other news, major shareholder Lynx1 Capital Management Lp bought 80,069 shares of the stock in a transaction that occurred on Friday, December 19th. The stock was bought at an average cost of $0.90 per share, for a total transaction of $72,062.10. Following the acquisition, the insider directly owned 7,937,416 shares of the company’s stock, valued at $7,143,674.40. The trade was a 1.02% increase in their position. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. Over the last quarter, insiders bought 161,801 shares of company stock worth $145,621. 4.35% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On TScan Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Aberdeen Group plc boosted its stake in shares of TScan Therapeutics by 52.0% in the 3rd quarter. Aberdeen Group plc now owns 1,354,820 shares of the company’s stock valued at $2,466,000 after buying an additional 463,372 shares during the period. BVF Inc. IL lifted its stake in TScan Therapeutics by 6.9% during the second quarter. BVF Inc. IL now owns 5,226,074 shares of the company’s stock worth $7,578,000 after purchasing an additional 336,600 shares during the last quarter. Renaissance Technologies LLC lifted its stake in TScan Therapeutics by 37.5% during the fourth quarter. Renaissance Technologies LLC now owns 1,141,069 shares of the company’s stock worth $1,141,000 after purchasing an additional 311,150 shares during the last quarter. Jane Street Group LLC boosted its holdings in TScan Therapeutics by 377.5% in the fourth quarter. Jane Street Group LLC now owns 388,284 shares of the company’s stock valued at $388,000 after purchasing an additional 306,968 shares in the last quarter. Finally, Marshall Wace LLP grew its position in shares of TScan Therapeutics by 627.5% in the 4th quarter. Marshall Wace LLP now owns 339,240 shares of the company’s stock valued at $339,000 after buying an additional 292,610 shares during the last quarter. Hedge funds and other institutional investors own 82.83% of the company’s stock.

About TScan Therapeutics

TScan Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of T-cell receptor (TCR) therapies for the treatment of cancer. Leveraging its proprietary T-Scan platform, the company seeks to identify high-affinity TCRs that recognize intracellular tumor antigens presented on the surface of cancer cells. TScan’s approach aims to broaden the reach of immunotherapy beyond current targets by unlocking a wider array of cancer-associated proteins.

The company’s pipeline includes multiple preclinical and early-stage clinical programs in both hematologic malignancies and solid tumors.